JP2006525351A5 - - Google Patents

Download PDF

Info

Publication number
JP2006525351A5
JP2006525351A5 JP2006514176A JP2006514176A JP2006525351A5 JP 2006525351 A5 JP2006525351 A5 JP 2006525351A5 JP 2006514176 A JP2006514176 A JP 2006514176A JP 2006514176 A JP2006514176 A JP 2006514176A JP 2006525351 A5 JP2006525351 A5 JP 2006525351A5
Authority
JP
Japan
Prior art keywords
claudin
antibody
kit
cancer
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006514176A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006525351A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/013436 external-priority patent/WO2004098647A2/en
Publication of JP2006525351A publication Critical patent/JP2006525351A/ja
Publication of JP2006525351A5 publication Critical patent/JP2006525351A5/ja
Pending legal-status Critical Current

Links

JP2006514176A 2003-04-30 2004-04-30 ガンを診断および治療するための方法 Pending JP2006525351A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46690503P 2003-04-30 2003-04-30
PCT/US2004/013436 WO2004098647A2 (en) 2003-04-30 2004-04-30 Claudins’ underexpression as markers of tumor metastasis

Publications (2)

Publication Number Publication Date
JP2006525351A JP2006525351A (ja) 2006-11-09
JP2006525351A5 true JP2006525351A5 (https=) 2007-06-07

Family

ID=33434995

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006514176A Pending JP2006525351A (ja) 2003-04-30 2004-04-30 ガンを診断および治療するための方法

Country Status (8)

Country Link
US (1) US20040253211A1 (https=)
EP (1) EP1620732A2 (https=)
JP (1) JP2006525351A (https=)
CN (1) CN100575955C (https=)
CA (1) CA2523870A1 (https=)
MX (1) MXPA05011644A (https=)
NO (1) NO20055449L (https=)
WO (1) WO2004098647A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2672581A1 (en) * 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
JPWO2008114733A1 (ja) * 2007-03-16 2010-07-01 協和発酵キリン株式会社 抗Ｃｌａｕｄｉｎ−４抗体
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
KR101741898B1 (ko) 2015-05-27 2017-06-01 울산대학교 산학협력단 Claudin 7을 포함하는 방사선 반응성 위암 진단용 바이오마커 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554388A (en) * 1989-02-25 1996-09-10 Danbiosyst Uk Limited Systemic drug delivery compositions comprising a polycationi substance
US5744166A (en) * 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
GB9412394D0 (en) * 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
GB9419979D0 (en) * 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
GB9522351D0 (en) * 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US5976800A (en) * 1996-06-28 1999-11-02 The Regents Of The University Of California Enhancement of cancer cell death
DE69831421T2 (de) * 1997-12-02 2006-06-22 Archimedes Development Ltd. Zusammensetzungen zur nasalen verabreichung
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US6248864B1 (en) * 1997-12-31 2001-06-19 Adherex Technologies, Inc. Compounds and methods and modulating tissue permeability
US7279294B2 (en) * 2000-04-03 2007-10-09 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services, Nih Tumor markers in ovarian cancer
CN1234727C (zh) * 2000-06-01 2006-01-04 北京双鹭药业股份有限公司 人胸腺素α原基因突变体合成、表达及应用
AU2003217397A1 (en) * 2002-02-14 2003-09-04 The Johns Hopkins University School Of Medecine Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer

Similar Documents

Publication Publication Date Title
ES2491222T3 (es) Marcadores de expresión génica para el pronóstico de cáncer colorrectal
CN102667472B (zh) Tivozanib应答预测
JP2019150027A5 (https=)
KR102341336B1 (ko) 만성간질환의 예후 예측용 바이오마커 조성물
CN103097548A (zh) 基于多癌症侵袭相关机制的生物标记
WO2010151789A1 (en) Salivary transcriptomic and microbial biomarkers for pancreatic cancer
JP2014509515A5 (https=)
CN104136630A (zh) 诊断和预示乳腺癌的标志物
CN107208159A (zh) 宿主dna作为克罗恩氏病的生物标记物
JP2006525351A5 (https=)
KR20110042678A (ko) 전립선암에 대한 바이오마커 및 이를 이용한 전립선암 진단
CN108884495B (zh) 基因标记预测肝细胞癌对经导管动脉化疗栓塞(tace)的应答
KR101815253B1 (ko) 간 섬유화 진단용 바이오마커 cxcl14
US20130190321A1 (en) Methods and compositions relating to proliferative disorders of the prostate
ES2380651T3 (es) Biomarcadores y procedimientos para determinar la sensibilidad a moduladores de recpetor 2 del factor de crecimiento endotelial vascular
WO2021013891A1 (en) Methods for diagnosing cancer
US10895574B2 (en) Left-right gene expression signature for triple negative breast cancer
KR102259695B1 (ko) 대장암에 대한 항암제 감수성 예측을 위한 신규 바이오마커
CN118613596A (zh) 用于检测区分侵袭性前列腺癌与惰性形式的生物标志物以及侵袭性前列腺癌的治疗
KR102136747B1 (ko) 장형 위암의 예후 진단 마커
CN113832228A (zh) 生物标志物在预测直肠癌对术前放化疗联合全直肠系膜切除术的敏感性中的应用
KR20220061425A (ko) 항암제 반응성 예측용 바이오마커 및 이의 용도
US20240093307A1 (en) Serum exosomal sf3b4 marker composition for diagnosing early stage hepatocellular carcinoma for noninvasive in vitro diagnosis
GB2630774A (en) Lung cancer biomarkers
CN119619512A (zh) Fkbp9检测剂在制备肝癌诊断或预后评估的产品中的应用